Roth Capital adjusted the firm’s price target on Cellectar Biosciences (CLRB) to $18 from $3 and keeps a Buy rating on the shares post the Q2 report. The new price target largely reflects the company’s reverse split.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB: